AIM ImmunoTech Q3 2024 Investor Presentation | Ampligen Clinical Programs

AIM ImmunoTech is a late-stage clinical immuno-pharma company developing therapeutics across immuno-oncology, immune disorders, and viral diseases. The company's lead program, Ampligen®, is an immuno-modulator with broad-spectrum activity demonstrated in human clinical studies and published in peer-reviewed journals. Multiple value-driving clinical inflection points are anticipated across high-value disease indications.